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Myeloproliferative neoplasms (MPNs) are hematologic malignancies that cause 
uncontrolled blood cell growth and can progress to secondary acute myeloid leukemia 
(sAML). While there are therapies for AML and MPN patients, only a fraction of 
them are suitable to the individual, and the progress of standard chemotherapy has 
remained largely stagnant over the past few decades. Therefore, the investigation of 
MPN drug candidates such as pevonedistat is imperative.  Pevonedistat is a NEDD8 
activating enzyme inhibitor currently in clinical trials for AML. The inhibitor is known 
to impede NF-kB signaling as well as other signaling pathways associated with MPN 
pathogenesis; therefore, it is crucial to characterize the effects of pevonedistat on a 
variety of pathways. While the JAK-STAT pathway is primarily associated with AML 
and myelofibrosis, inhibition of JAK2 does not completely diminish MPN pathogenesis. 
Therefore, it is likely that activation of other signaling processes drive cell proliferation 
in addition to JAKSTAT. Previous studies in the Oh Lab have shown that the NF-kB 
pathway is hyperactivated in sAML and MF hematopoietic stem and progenitor cells 
(HSPC), identifying the NF-kB pathway as a potential target of pevonedistat. We have 
found that pevonedistat lowers cell viability in human erythroleukemia (HEL) cell line in 
a dose-dependent manner. Furthermore, pevonedistat in combination with JNK-IN-8, 
an inhibitor of the JNK-AP1 pathway, lowers cell viability in an additive fashion. The 
combination of pevonedistat and JNK-IN-8 may be superior to pevonedistat alone, and 
thus we are currently exploring this possibility.
